Topics Daily Digest Tags

© 2026 ChemBrief · Powered by ECHEMI.COM · Chemical news, 3 minutes a day

Topics Daily Digest Tags

Kasvu Therapeutics Pursues Novel Neuroplasticity Target for Depression — ChemBrief Topics

Kasvu Therapeutics Pursues Novel Neuroplasticity Target for Depression

21 hours ago

Kasvu Therapeutics secured €30 million in Series A funding to advance KTX-0141 for major depressive disorder. The startup targets the TrkB receptor to induce neuroplasticity without the hallucinogenic effects of psychedelics.

Kasvu Therapeutics Pursues Novel Neuroplasticity Target for Depression

cen

2026-09-24

Kasvu Therapeutics Pursues Novel Neuroplasticity Target for Depression

Related tags

Kasvu TherapeuticsCompany

KTX-0141Product

Related topics

PPG promotes Kalsani Ukraine strikes oil Wacker profit rises Keda invests in anode Victrex Evonik Gain

Topic

Kasvu raises 30M

Scan to get the App